DNA OncoNex - Lung Cancer
Lung cancer stands as the leading cause of cancer-related mortality worldwide, with approximately 2 million new cases and 1.8 million deaths annually. The complexity of lung cancer, combined with its aggressive nature, underscores the need for advanced diagnostic tools to enhance patient care and treatment outcomes. DNA OncoNex offers a cutting-edge solution through its comprehensive Next Generation Sequencing (NGS) assay, which targets 100 genes associated with lung cancers. This advanced diagnostic tool provides a detailed genomic profile of tumors, helping to identify novel genetic aberrations and potential therapeutic targets.
Lung cancer is primarily categorized into two main types based on histological appearance: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC, which constitutes over 80% of lung cancer cases, is further divided into subtypes, including adenocarcinoma, large-cell carcinoma, and squamous cell carcinoma. Understanding the genetic landscape of these cancers is crucial for effective treatment planning and improving patient outcomes.
DNA OncoNex leverages NGS technology to provide a comprehensive analysis of up to 100 genes related to lung cancer. This analysis includes:
- Identification of Driver Mutations: Mutations in specific genes drive the development and progression of lung cancer. Identifying these mutations helps in understanding the mechanisms behind tumor growth and spread.
- Drug Profiling for Targeted Therapy: By identifying genetic mutations, DNA OncoNex enables the selection of targeted therapies that are more likely to be effective against specific tumor types.
- Predictive Genomic Biomarker Identification: The assay helps in identifying biomarkers that predict responses to various treatments, guiding personalized therapy choices.
- Novel Genetic Aberrations: NGS technology allows for the detection of both known and novel genetic variants, providing insights into potential new targets for therapy.
Clinical Utility
The clinical utility of DNA OncoNex in lung cancer diagnosis and management is significant:
- Early and Accurate Diagnosis: NGS provides a detailed genomic profile that aids in the accurate diagnosis of lung cancer subtypes and their molecular characteristics.
- Targeted Treatment: By identifying specific genetic mutations, the assay helps in selecting targeted therapies that can significantly improve treatment efficacy and minimize adverse effects.
- Prognostic Insights: The assay offers insights into the prognosis of lung cancer patients based on the genetic profile of their tumors.
- Monitoring Treatment Response: Regular genomic profiling can help monitor how well a treatment is working and adjust the therapeutic approach as needed.
- Reduced Time to Diagnosis: The comprehensive nature of the NGS panel reduces the time required to diagnose and understand the cancer, leading to faster initiation of appropriate treatments.
When to Consider DNA OncoNex
DNA OncoNex is particularly beneficial in the following scenarios:
- Initial Diagnosis: For patients diagnosed with lung cancer, especially those with NSCLC, NGS provides critical information on genetic mutations that guide treatment decisions.
- Treatment Planning: Patients with advanced or refractory lung cancer can benefit from targeted therapies identified through genetic profiling.
- Prognostic Evaluation: DNA OncoNex helps in assessing the likely progression of the disease based on the identified genetic alterations.
- Clinical Trials: Patients considering participation in clinical trials may need detailed genetic information to meet specific trial criteria.
MapmyGenome Offerings
MapmyGenome provides a comprehensive suite of services through its DNA OncoNex assay:
- Focus on 100 Cancer Genes: The assay covers a broad spectrum of genes associated with lung cancer, ensuring a thorough analysis.
- Guidelines-Based Screening: Gene screening follows the National Comprehensive Cancer Network (NCCN) guidelines to ensure clinically relevant results.
- Genetic Counseling: Expert genetic counseling is offered to help patients and their families understand the results and explore management and treatment options.
- Reporting: Pathogenic and likely pathogenic variants are reported according to ACMG (American College of Medical Genetics) guidelines, providing clear and actionable insights.
- Advanced Bioinformatics: MapmyGenome utilizes a state-of-the-art bioinformatics pipeline for accurate and reliable analysis of genetic data.
Test Specification
| Technique | Coverage | Variant types | TAT | Sample requirements |
|---|---|---|---|---|
| NGS | 800 - 1000X | SNV | 3 - 4 weeks | FFPE (Formalin-Fixed Paraffin-Embedded) Sample - Somatic cases, Blood Sample - Germline cases |